Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET Journal Article
| Authors: | Dunphy, M. P.; Lewis, J. S. |
| Article Title: | Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET |
| Abstract: | This review article discusses PET agents, other than <sup>18</sup>F-FDG, with the potential to monitor the response to therapy before, during, or after therapeutic intervention. This review deals primarily with non- <sup>18</sup>F-FDG PET tracers that are in the final stages of preclinical development or in the early stages of clinical application for monitoring the therapeutic response. Four sections related to the nature of the tracers are included: radiotracers of DNA synthesis, such as the 2 most promising agents, the thymidine analogs 3′-<sup>18</sup>F-fluoro-3′-deoxythymidine and <sup>18</sup>F-1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl) thymine; agents for PET imaging of hypoxia within tumors, such as <sup>60/62/64</sup>Cu-labeled diacetylbis( N<sup>4</sup>- methylthiosemicarbazone) and <sup>18</sup>F-fluoromisonidazole; amino acids for PET imaging, including the most popular such agent, L-[methyl- <sup>11</sup>C]methionine; and agents for the imaging of tumor expression of androgen and estrogen receptors, such as 16β-<sup>18</sup>F-fluoro- 5α-dihydrotestosterone and 16α-<sup>18</sup>F-fluoro-17β- estradiol, respectively. Copyright © 2009 by the Society of Nuclear Medicine, Inc. |
| Keywords: | treatment outcome; treatment response; unclassified drug; review; doxorubicin; fluorouracil; nonhuman; gemcitabine; ibritumomab tiuxetan; methotrexate; temozolomide; positron emission tomography; radiopharmaceuticals; dna synthesis; neoplasms; cell proliferation; unindexed drug; epidermal growth factor receptor 2; patient monitoring; hypoxia; drug uptake; glioblastoma; lymphoma; fluorodeoxyglucose f 18; positron-emission tomography; radiopharmaceutical agent; heat shock protein 90; tamoxifen; 1 fluoro 3 (2 nitro 1 imidazolyl) 2 propanol f 18; proliferation; estrogen receptor; trastuzumab; single photon emission computer tomography; pet; steroid receptors; therapy monitoring; 1 (2' deoxy 2' fluoro beta dextro arabinofuranosyl)thymine f 18; 1 amino 3 fluorocyclobutanecarboxylic acid f 18; 16beta fluoro 5alpha dihydrotestosterone f 18; 3' fluorothymidine f 18; acetic acid c 11; choline c 11; diacetylbis(n4 methylthiosemicarbazone) cu 60; diacetylbis(n4 methylthiosemicarbazone) cu 62; diacetylbis(n4 methylthiosemicarbazone) cu 64; estradiol f 18; methylmethionine c 11; o (2 fluoroethyl)tyrosine f 18; sex hormone binding globulin; thymidine kinase 1; tositumomab i 131; cancer scintiscanning; hypoxemia; radioisotopes |
| Journal Title: | Journal of Nuclear Medicine |
| Volume: | 50 |
| Issue: | SUPPL. 1 |
| ISSN: | 0161-5505 |
| Publisher: | Society of Nuclear Medicine |
| Date Published: | 2009-05-01 |
| Start Page: | 106S |
| End Page: | 121S |
| Language: | English |
| DOI: | 10.2967/jnumed.108.057281 |
| PUBMED: | 19380404 |
| PROVIDER: | scopus |
| PMCID: | PMC2963172 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 12" - "Export Date: 30 November 2010" - "CODEN: JNMEA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work